Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

946 - Surgical outcomes of primary retroperitoneal sarcoma: an institutional experience


20 Dec 2015


Poster presentation 2


Faith Leong


Annals of Oncology (2015) 26 (suppl_9): 108-110. 10.1093/annonc/mdv530


F.Q.H. Leong1, A. Rauff2, R. Parameswaran2

Author affiliations

  • 1 Division Of Endocrine And General Surgery, University Surgical Cluster, National University Hospital, 119074 - Singapore/SG
  • 2 Division Of Endocrine And General Surgery, University Surgical Cluster, National University Hospital, Singapore/SG


Abstract 946


Liposarcoma is the single most common soft tissue sarcoma in the retroperitoneum. We reviewed our experience with retroperitoneal liposarcoma to identify factors predictive of outcomes.


All patients with retroperitoneal liposarcoma (LPS) treated at a tertiary centre between 1998 and 2014 were reviewed. Multivariable Cox regression analyses were performed to identify factors predictive of relapse free survival (RFS) and overall survival (OS).


We identified 22 patients with primary retroperitoneal LPS. Median tumour size was 19.25 (± 9.62) cm; 27% were multifocal. Tumour grades were well differentiated in 55% of patients, pleomorphic in 22% of patients and high in 23%. Resections were complete (R0/R1) in 45% of patients and incomplete (R2) in 41% (unknown 14%). Resection of contiguous organs was required in 20 (91%) to achieve gross surgical margins. Median follow-up was 68 months. 15 patients (68%) experienced local recurrence or progression, with 45% occurring in the retroperitoneum. Cohort mortality was 32%. Mean RFS and OS were (41.83 ± 38.11) months and (67.50 ± 67.01) months, respectively, and were worse with R2 resection. On multivariate analysis only histotype was predictive of RFS.


In this cohort of primary retroperitoneal sarcoma, extent of surgical resection and histological grade impacted patient outcomes.

Clinical trial identification

Not applicable


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings